Phuturdex › Dates to watch
Drugs in development · updated 30 October 2026
Dates to watch in October 2026
The regulatory and clinical-trial dates of October 2026 for drugs in development, from official sources: 0 EU decisions expected, 125 phase III trials with a registered primary completion date (41 of them for experimental drugs, not yet approved in the US) and 0 US exclusivities or patents ending. Every date links to its source.
Information only, not investment advice. Dates are those registered by EMA, FDA and ClinicalTrials.gov; trials often finish later than registered, and the European Commission may decide earlier or later than the usual 67 days after a positive CHMP opinion.
EU decisions expected
No EU decision expected this month from the opinions published so far.
Phase III trials completing
125 active phase III trials have a primary completion date registered for October 2026. Below, the first 30, drugs not yet approved in the US first; the full list, by company and disease, is in Phuturdex.
| Drug | Trial | Sponsor |
|---|---|---|
| Sintilimab | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC · NCT05608200 | Second Affiliated Hospital of Guangzhou Medical University |
| Adebrelimab, SHR-8068, Sintilimab | A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Adva · NCT06618664 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Ivonescimab | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer · NCT06591520 | Akeso |
| Cadonilimab, Sugemalimab | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC · NCT06617416 | Akeso |
| Sacituzumab Tirumotecan | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) · NCT06356311 | Merck Sharp & Dohme LLC |
| Dalpiciclib | Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Rec · NCT04842617 | Jiangsu HengRui Medicine Co., Ltd. |
| Melatonin | Effect of Melatonin Administration on Systemic Lupus Erythematosus Patients · NCT07721324 | Ain Shams University |
| Telitacicept | Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome · NCT06125405 | The Children's Hospital of Zhejiang University School of Medicine |
| BL-M07D1 | A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer · NCT06316531 | Sichuan Baili Pharmaceutical Co., Ltd. |
| Famitinib | Neoadjuvant SNF Precision Therapy Phase III · NCT06913777 | Fudan University |
| Ianalumab | Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) · NCT05653349 | Novartis Pharmaceuticals |
| Afimkibart | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to · NCT06588855 | Hoffmann-La Roche |
| Retatrutide | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Gl · NCT06297603 | Eli Lilly and Company |
| Contezolid, Delamanid, Para-Aminosalicylic Acid | Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Be · NCT06081361 | Beijing Chest Hospital |
| Povorcitinib | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) · NCT06516952 | Incyte Corporation |
| Povorcitinib | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) · NCT06516965 | Incyte Corporation |
| Azetukalner | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder · NCT06775379 | Xenon Pharmaceuticals Inc. |
| JSKN003 | JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer · NCT06846437 | Shanghai JMT-Bio Inc. |
| HL-1186 | Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery · NCT07699601 | Shanghai Huilun Pharmaceutical Co., Ltd. |
| HL-1186 | Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery · NCT07709598 | Shanghai Huilun Pharmaceutical Co., Ltd. |
| D-1553 | D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Pri · NCT06300177 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Barzolvolimab | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria · NCT06445023 | Celldex Therapeutics |
| Barzolvolimab | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) · NCT06455202 | Celldex Therapeutics |
| AND017 | A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia · NCT07494409 | Kind Pharmaceuticals LLC |
| Rupatadine | Effect of Some Drugs on Rheumatoid Arithritis Activity · NCT03770923 | Sherief Abd-Elsalam |
| Cemdisiran | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal · NCT05133531 | Regeneron Pharmaceuticals |
| Litifilimab | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus · NCT05531565 | Biogen |
| Palazestrant | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer · NCT06016738 | Olema Pharmaceuticals, Inc. |
| Ziltivekimab | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation · NCT06200207 | Novo Nordisk A/S |
| SEP-363856 | A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia · NCT06894212 | Otsuka Pharmaceutical Development & Commercialization, Inc. |
US exclusivities and patents ending
None registered this month.
The whole calendar, for the drugs you follow
In Phuturdex the calendar covers the next 36 months, with filters by company, disease and type of date, and an email when a date changes. Free until 31 March 2027.
Source: Phuturdex analysis of EMA, FDA (Orange Book, Purple Book, orphan designations) and ClinicalTrials.gov (U.S. National Library of Medicine) data, updated 30 October 2026. Information only, not investment, medical or legal advice.